pnb0408 dihexa human trial Dihexa (also known as PNB-0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the blood–brain barrier and has shown synaptogenic effects Dihexa Dosage Protocol: Doses, Evidence
Description
doi: 10.1016/j.jad.2013.04.044 240 JackaFNMykletunABerkMBjellandITellGS
Cycling and Duration Standard protocols recommend running BPC-157 for 4 to 8 weeks depending on injury severity, followed by a 2 to 4 week break
What markers will be monitored during treatment
[DOI] [PubMed] [Google Scholar] 73.Wever K.E., Menting T.P., Rovers M., van der Vliet J.A., Rongen G.A., Masereeuw R., Ritskes-Hoitinga M., Hooijmans C.R., Warl M
Nonetheless, it is getting frequently prescribed for increasing muscle mass and putative, unproven , anti-aging benefit
doi:10.1097/DCR.0000000000001556 16
